TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
iX Biopharma Ltd. ( (SG:42C) ) has shared an announcement.
iX Biopharma Ltd. reported a 39% revenue growth to $3.7 million in the first half of 2025, primarily driven by increased sales in specialty pharmaceuticals and nutraceuticals, including strong demand for medicinal cannabis products in Australia. The company also improved its operational efficiency by reducing operating expenses and headcount, which led to a 33% reduction in operating cash burn and a 20% decrease in adjusted EBITDA loss, signaling progress towards profitability.
More about iX Biopharma Ltd.
iX Biopharma Ltd. operates in the pharmaceutical industry, focusing on specialty pharmaceuticals and nutraceuticals. The company is known for its medicinal cannabis products and flagship nutraceutical products, SL-NAD+ and LumeniX, with a market focus primarily in Australia.
YTD Price Performance: 15.00%
Average Trading Volume: 182,897
Technical Sentiment Consensus Rating: Buy
Current Market Cap: S$19.35M
For an in-depth examination of 42C stock, go to TipRanks’ Stock Analysis page.